tiprankstipranks
RELIEF THERAPEUTICS Holding (RLFTF)
OTHER OTC:RLFTF

RELIEF THERAPEUTICS Holding (RLFTF) Stock Price & Analysis

290 Followers

RLFTF Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$0.01 - $8.50
Previous Close$1.82
Volume1.06K
Average Volume (3M)3.74K
Market Cap
$20.39M
Enterprise Value$3.85M
Total Cash (Recent Filing)CHF19.24M
Total Debt (Recent Filing)CHF2.69M
Price to Earnings (P/E)N/A
Beta0.68
Mar 29, 2024
EPS EstimateN/A
Next Dividend Ex-DateN/A
Expense RatioN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding11,018,501
10 Day Avg. Volume3,958
30 Day Avg. Volume3,736
Standard Deviation0.20
R-Squared0.15
Alpha-0.08
Financial Highlights & Ratios
Price to Book (P/B)-1.24
Price to Sales (P/S)1.31
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0

Financials

Annual

RLFTF FAQ

What was RELIEF THERAPEUTICS Holding’s price range in the past 12 months?
RELIEF THERAPEUTICS Holding lowest stock price was $0.01 and its highest was $8.50 in the past 12 months.
    What is RELIEF THERAPEUTICS Holding’s market cap?
    Currently, no data Available
    When is RELIEF THERAPEUTICS Holding’s upcoming earnings report date?
    RELIEF THERAPEUTICS Holding’s upcoming earnings report date is Mar 29, 2024 which is in 30 days.
      How were RELIEF THERAPEUTICS Holding’s earnings last quarter?
      RELIEF THERAPEUTICS Holding released its earnings results on Sep 15, 2023. The company reported -$5.8 earnings per share for the quarter, missing the consensus estimate of N/A by -$5.8.
        Is RELIEF THERAPEUTICS Holding overvalued?
        According to Wall Street analysts RELIEF THERAPEUTICS Holding’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
          Does RELIEF THERAPEUTICS Holding pay dividends?
          RELIEF THERAPEUTICS Holding does not currently pay dividends.
          What is RELIEF THERAPEUTICS Holding’s EPS estimate?
          RELIEF THERAPEUTICS Holding’s EPS estimate for its next earnings report is not yet available.
          How many shares outstanding does RELIEF THERAPEUTICS Holding have?
          Currently, no data Available
          What happened to RELIEF THERAPEUTICS Holding’s price movement after its last earnings report?
          RELIEF THERAPEUTICS Holding reported an EPS of -$5.8 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -22.535%.
            Which hedge fund is a major shareholder of RELIEF THERAPEUTICS Holding?
            Currently, no hedge funds are holding shares in RLFTF
            ---

            RELIEF THERAPEUTICS Holding Stock Smart Score

            Company Description

            RELIEF THERAPEUTICS Holding

            Relief Therapeutics Holding AG is a Switzerland based drug development company focusing on clinical stage projects, primarily developing drugs of natural human origin. It is engaged in its operations for diabetic complications and respiratory diseases. The company is focused on developing drug candidates namely, Aviptadil and Atexakin alfa. Aviptadil is a biologically active endogenous human peptide that possesses anti-proliferative, anti-inflammatory, and immune regulatory activities. Atexakin alfa is a low dosage formulation of interleukin-6 that exhibits functions in diverse tissues and organs. The group operates its functions in Switzerland.
            ---
            Similar Stocks
            Company
            Price & Change
            Follow
            Acasti Pharma
            Aldeyra Therapeutics
            Actinium Pharmaceuticals
            Bellicum Pharmaceuticals
            Popular Stocks
            ---
            What's Included in PREMIUM?
            Make informed decisions based on Top Analysts' activity
            Know what industry insiders are buying
            Get actionable alerts from top Wall Street Analysts
            Find out before anyone else which stock is going to shoot up
            Get powerful stock screeners & detailed portfolio analysis